Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers

European Journal of Cancer Prevention

Volumn 21, Issue 2, 2012, Pages 199-204

  Primas, Helga ^a   Kroiss, Regina ^a   Kalteis, Karin ^a   Rappaport, Christine ^a   Muhr, Daniela ^a   Primas, Christian ^a   Kubista, Ernst ^a   Horvat, Reinhard ^a   Oefner, Peter ^a   Singer, Christian ^a   Wagner, Teresa ^a  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

BRCA1; BRCA2; Lifestyle factors; Ovarian cancer; Preneoplastic changes; Prophylactic salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; FEMALE; GENE MUTATION; GENETIC COUNSELING; HETEROZYGOTE; HISTOLOGY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; OBESITY; OVARY CANCER; OVARY DISEASE; OVARY DYSPLASIA; OVARY TUMOR; PAPILLOMATOSIS; PERITONEUM ADENOCARCINOMA; PHYSICAL ACTIVITY; PRECANCER; PREGNANCY; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SMOKING;

ADULT; AGED; FAMILY HEALTH; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; LIFE STYLE; MIDDLE AGED; MUTATION; OVARIECTOMY; OVERWEIGHT; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84857945473     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32834c9b22     Document Type: Article

References (44)

1. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B (2004). Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22:1045-1054. (Pubitemid 41095037)
2. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA (1994). Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 71:510-518. (Pubitemid 24338158)
3. Auersperg N, Maines-Bandiera SL, Booth JH, Lynch HT, Godwin AK, Hamilton TC (1995). Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. Am J Obstet Gynecol 173:558-565.
4. Barakat R, Federici M, Saigo P, Robson M, Offit K, Boyd J (2000). Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 89:383-389.
5. Cramer DW, Welch WR (1983). Determinants of ovarian cancer risk. Interferences regarding pathogenesis. J Natl Cancer Inst 71:717-721. (Pubitemid 14232385)
6. Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, et al. (1998). p53 mutation with frequent novel condons but not a mutator phenotype in B. Oncogene 17:1681-1689.
7. Fathalla MF (1971). Incessant ovulation - a factor in ovarian neoplasia? Lancet 2:163.
8. Feeley KM, Wells M (2001). Precursor lesions of ovarian epithelial malignancy. Histopathology 38:87-95. (Pubitemid 32193623)
9. Greer JB, Modugno F, Ness RB, Allen GO (2006). Anthropometry and the risk of epithelial ovarian cancer. Cancer 106:2247-2257. (Pubitemid 43673248)
10. Gusberg SB, Deligdisch L (1984). Ovarian dysplasia. A study of identical twins. Cancer 54:1-4. (Pubitemid 14117035)
11. Hoyo C, Berchuck A, Halabi S, Bentley RC, Moorman P, Calingaert B, Schildkraut JM (2005). Anthropometric measurements and epithelial ovarian cancer risk in African-American and white women. Cancer Causes Control 16:955-963. (Pubitemid 41191420)
12. Karlan BY (2004). Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol Oncol 92:519-520.
13. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 23:1609-1615. (Pubitemid 34755668)
14. Kuper H, Cramer DW, Titus-Ernstoff L (2002). Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status? Cancer Causes Control 13:455-463. (Pubitemid 34666601)
15. Land JA (1993). Ovulation, ovulation induction and ovarian carcinoma. Baillieres Clin Obstet Gynaecol 7:455-472.
16. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P (2002). Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 87:52-56. (Pubitemid 36027101)
17. Lubin F, Chetrit A, Freedman LS, Alfandary E, Fishler Y, Nitzan H, Zultan A, Modan B (2003). Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol 157:113-120. (Pubitemid 36077442)
18. Mittal KR, Zeleniuch-Jacquote A, Cooper JL, Demopoulos RI (1993). Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 12:59-63. (Pubitemid 23013912)
19. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al.; National Israel Ovarian Cancer Study Group (2001). Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235-240. (Pubitemid 32695062)
20. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. (1998). Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary ovarian cancer clinical study group. N Engl J Med 339:424-428. (Pubitemid 28377683)
21. Okamura H, Katabuchi H (2001). Detailed morphology of human ovarian surface epithelium focusing on its metaplastic and neoplastic capability. Ital J Anat Embryol 106:263-276.
22. Olsen CM, Bain CJ, Jordan SJ, Nagle CM, Green AC, Whiteman DC, et al.; Australian Ovarian Cancer Study Group (2007). Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and a meta-analysis. Cancer Epidemiol Biomarkers Prev 16:2321-2330 Review.
23. Olsen C, Nagle C, Whiteman D, Green A, Webb P; Australian cancer study and Australian ovarian cancer study group (2008). Body size and risk of epithelial ovarian and related cancers: a population-based case-control study. Int J Cancer 123:450-456.
24. Peterson NB, Trentham-Dietz A, Newcomb PA, Chen Z, Gebretsadik T, Hampton JM, et al. (2006). Relation of anthropometric measurements to ovarian cancer risk in a population-based case-control study (United States). Cancer Causes Control 17:459-467.
25. Piver MS, Wong C (1998). Role of prophylactic surgery for women with genetic predisposition to cancer. Clin Obstet Gynaecol 41:215-224. (Pubitemid 28114642)
26. Piver MS, Barlow JJ, Sawyer DM (1982). Familial ovarian cancer: increasing in frequency? Obstet Gynecol 60:397-400. (Pubitemid 12048140)
27. Piver MS, Goldberg JM, Tsukada Y, Mettlin CJ, Jishi MF, Natarajan N (1996). Characteristics of familial ovarian cancer: a report of the first 1000 families in the Gilda Radner familial ovarian cancer registry. Eur J Gynaecol Oncol 17:169-176. (Pubitemid 26168145)
28. Prat J, Ribé A, Gallardo A (2005). Hereditary ovarian cancer. Hum Pathol 36:861-870. (Pubitemid 41187904)
29. Qi Cai K, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, et al. (2006). Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecol Oncol 103:719-728. (Pubitemid 44602166)
30. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. Prevention and observation of surgical end points study group. N Engl J Med 346:1616-1622. (Pubitemid 34755669)
31. Resta L, Russo S, Colucci GA, Prat J (1993). Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 82:181-186. (Pubitemid 23217655)
32. Rhei E, Bogomolniy F, Federici M, Maresco D, Offit K, Robson M, et al. (1998). Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 58:3193.
33. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. (1997). National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Betesheda guidelines. J Natl Cancer Inst 89:1758-1762.
34. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N (1996). Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88:1810-1820. (Pubitemid 26425055)
35. Schlosshauer P, Cohen C, Penault-Llorca F, Miranda C, Bignon Y-L, Dauplat J, et al. (2003). Prophylactic oophorectomy. Cancer 98:2599-2606.
36. Scully RE (1993). Ovary, chapter 15. In: Henson DE, Albores-Saavedra F, editors. The Pathology of Incipient Neoplasia. Philadelphia: W.B. Saunders. pp. 279-293.
37. Stratton JF, Buckley CH, Lowe D, Ponder BAJ (1999). Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. J Natl Cancer Inst 91:626-628. (Pubitemid 29194049)
38. Tok E, Ertunc D, Tataroglu C, Yazici G, Kanat H, Dilek S (2006). Clinicopathologic study of the putative precursor lesions of epithelial ovarian cancer in lowrisk women. Int J Gynecol Cancer 16:501-506.
39. Werness B, Afify A, Bielat K, Eltabbakh G, Piver S, Paterson J (1999). Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 30:151-157. (Pubitemid 29086945)
40. Werness B, Eltabbakh G (2001). Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. Int J Gynecol Pathol 20:48-63. (Pubitemid 32041757)
41. Werness BA, Parvatiyar P, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, et al. (2000). Ovarian carcinoma in situ with germline BRCA mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cncer Inst 92:1088-1091. (Pubitemid 30616483)
42. Whittemore AS, Balise RR, Pharaoh PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ (2004). Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91:1911-1915. (Pubitemid 40065520)
43. WHO (1995). Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 854:1-452.
44. Zajicek J (1977). Ovarian cystomas and ovulation, a histogenetic concept. Tumori 63:429-435.